Compare BioNTech SE - ADR (BNTX) vs Google Inc (GOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Google Inc — how do they compare? BioNTech SE - ADR trades at $92.46 (market cap $23.30B), while Google Inc trades at $343.74 (market cap $4.20T). The key difference: Google Inc is far larger — about 180.3× BioNTech SE - ADR's market cap, and Google Inc pays a 0.26% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | GOOG | |
|---|---|---|
Market Cap | $23.30B | $4.20T |
Sector | Health | Technology |
52-Week High | $119.34 | $399.06 |
52-Week Low | $83.89 | $200.19 |
Enterprise Value | $6.60B | $4.08T |
Volume | — | 1,511,127 |
Dividend Yield | — | 0.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.12, down 0.73% on the day, amid weak COVID-19 vaccine demand and a net loss of $1.14 billion in 2025. The stock shows a bullish technical signal with support near $92 and resistance at $93, while fundamentals reveal a high P/E of 161.14 and negative profitability margins. Recent news highlights a CEO transition to Guido Oelkers and a lowered 2026 sales outlook due to softening vaccine revenue.
The outlook remains cautious with declining revenues and persistent losses, though a strong cash position of $16.78 billion supports its oncology pipeline development. Risks include execution challenges in shifting from COVID-19 dependence, while analyst consensus is bullish with a $121 price target, implying 31% upside from current levels.
Alphabet (GOOG) trades at $343.94, up 0.27% with strong fundamentals including 32.8% net profit margin and consistent earnings beats. Technical indicators show bearish momentum with support at $340 and resistance at $344. The company demonstrates robust revenue growth from $282.8B in 2022 to $402.8B in 2025, with AI investments driving future expansion despite current cash flow pressures from capital expenditures.
Alphabet presents a compelling investment case with 87% analyst buy ratings and $431.67 price target representing 25% upside. Key risks include AI spending pressure and regulatory investigations, but strong cloud growth and $514B backlog signal sustained demand. The stock's current valuation at 17.18 P/E offers attractive entry point for long-term growth investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Google Inc
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →
